JP2017503016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503016A5 JP2017503016A5 JP2016560857A JP2016560857A JP2017503016A5 JP 2017503016 A5 JP2017503016 A5 JP 2017503016A5 JP 2016560857 A JP2016560857 A JP 2016560857A JP 2016560857 A JP2016560857 A JP 2016560857A JP 2017503016 A5 JP2017503016 A5 JP 2017503016A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- diffractometer
- determined
- powder
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MZBLZLWXUBZHSL-FZNJKFJKSA-N CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@](C3)([C@@H]3C(F)F)C(NS(C3(C)CC3)(=O)=O)=O)=O)N1C2=O Chemical compound CC[C@H]([C@H](C1)Oc2nc(cc(cc3)OC)c3nc2C(CCCC[C@H](C2)[C@@H]2OC(N[C@H]2C(C)(C)C)=O)(F)F)[C@@H](C(N[C@](C3)([C@@H]3C(F)F)C(NS(C3(C)CC3)(=O)=O)=O)=O)N1C2=O MZBLZLWXUBZHSL-FZNJKFJKSA-N 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920427P | 2013-12-23 | 2013-12-23 | |
| US61/920,427 | 2013-12-23 | ||
| PCT/US2014/071310 WO2015100144A1 (en) | 2013-12-23 | 2014-12-18 | Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019020540A Division JP2019089819A (ja) | 2013-12-23 | 2019-02-07 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503016A JP2017503016A (ja) | 2017-01-26 |
| JP2017503016A5 true JP2017503016A5 (enExample) | 2018-01-18 |
| JP6568541B2 JP6568541B2 (ja) | 2019-08-28 |
Family
ID=52282995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016560857A Expired - Fee Related JP6568541B2 (ja) | 2013-12-23 | 2014-12-18 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
| JP2019020540A Pending JP2019089819A (ja) | 2013-12-23 | 2019-02-07 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019020540A Pending JP2019089819A (ja) | 2013-12-23 | 2019-02-07 | 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9562058B2 (enExample) |
| EP (1) | EP3087086B1 (enExample) |
| JP (2) | JP6568541B2 (enExample) |
| AR (1) | AR098958A1 (enExample) |
| AU (1) | AU2014370124A1 (enExample) |
| CA (1) | CA2934049A1 (enExample) |
| ES (1) | ES2708993T3 (enExample) |
| NZ (1) | NZ720887A (enExample) |
| PT (1) | PT3087086T (enExample) |
| TW (1) | TW201609752A (enExample) |
| UY (1) | UY35918A (enExample) |
| WO (1) | WO2015100144A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201906413T4 (tr) | 2013-12-23 | 2019-05-21 | Gilead Sciences Inc | Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi. |
| SG10202105371YA (en) | 2014-12-26 | 2021-07-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| JOP20170127A1 (ar) | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
| FI3706762T3 (fi) | 2017-12-07 | 2024-12-13 | Univ Emory | N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja |
| CN115417803B (zh) * | 2022-08-30 | 2023-10-03 | 四川同晟生物医药有限公司 | 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| SI2540350T1 (sl) * | 2008-07-22 | 2015-01-30 | Merck Sharp & Dohme Corp. | Kombinacije makrocikliäśnih kinoksalinske spojine, ki je hcv ns3 proteazni inhibitor z drugimi hcv uäśinkovinami |
| BR112013006693B1 (pt) * | 2010-09-21 | 2022-07-12 | Enanta Pharmaceuticals, Inc | Compostos inibidores da serino protease hcv derivada de prolina macrocíclica |
| WO2012040040A1 (en) * | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| DK2907816T3 (en) | 2011-11-16 | 2018-09-24 | Gilead Pharmasset Llc | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
-
2014
- 2014-12-18 WO PCT/US2014/071310 patent/WO2015100144A1/en not_active Ceased
- 2014-12-18 EP EP14824322.3A patent/EP3087086B1/en active Active
- 2014-12-18 NZ NZ720887A patent/NZ720887A/en not_active IP Right Cessation
- 2014-12-18 CA CA2934049A patent/CA2934049A1/en not_active Abandoned
- 2014-12-18 JP JP2016560857A patent/JP6568541B2/ja not_active Expired - Fee Related
- 2014-12-18 PT PT14824322T patent/PT3087086T/pt unknown
- 2014-12-18 US US14/575,966 patent/US9562058B2/en active Active
- 2014-12-18 ES ES14824322T patent/ES2708993T3/es active Active
- 2014-12-18 AU AU2014370124A patent/AU2014370124A1/en not_active Abandoned
- 2014-12-22 TW TW103144805A patent/TW201609752A/zh unknown
- 2014-12-23 AR ARP140104909A patent/AR098958A1/es unknown
- 2014-12-23 UY UY0001035918A patent/UY35918A/es not_active Application Discontinuation
-
2016
- 2016-12-21 US US15/387,318 patent/US9862728B2/en active Active
-
2019
- 2019-02-07 JP JP2019020540A patent/JP2019089819A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503016A5 (enExample) | ||
| JP2021530565A5 (enExample) | ||
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| RU2018145948A (ru) | Кристалл пирролопиримидина для получения jak-ингибитора | |
| JP2014501282A5 (enExample) | ||
| JP2014530818A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| JP2013530142A5 (enExample) | ||
| AR091138A1 (es) | Proceso para la preparacion de n-[5-(3,5-difluorobencil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetrahidropiran-4-ilamino)-benzamida | |
| JP2012521994A5 (enExample) | ||
| JP2016537346A5 (enExample) | ||
| JP2020500916A5 (enExample) | ||
| JP2009235100A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2014510746A5 (enExample) | ||
| JP2013538849A5 (enExample) | ||
| JP2016531852A5 (enExample) | ||
| JP2011088926A5 (enExample) | ||
| JP2015502371A5 (enExample) | ||
| JP2013520488A5 (enExample) | ||
| JP2015522592A5 (enExample) | ||
| JP2010514734A5 (enExample) |